To verify if the Acrp30 increase is a specific characteristic of CVID patients subjected to Ig replacement therapy, we evaluated its levels before, and 24 h and 7 days after Ig immunomodulating therapy in CIDP patients, and found that the total Acrp30 level did not change (see Table 2). This evidence concerns the gene ADIPOQ and chronic inflammatory demyelinating polyradiculoneuropathy.